Medtech takes on pain
Attempts to treat pain with non-opioid drugs have ended in repeated failures – but device makers have met with greater success.
Venture financing holds steady for device makers
Medtech VCs have plenty of cash, which is just as well because the IPO window is shut and locked.
Boston Scientific’s next move
The cardiovascular specialist needs to buy its way to growth – and it has marked an interest in a handful of smaller companies.
How low can medtech venture investment go?
2019’s medtech VC total is swollen by the sector’s first $1bn round, but counterintuitively the amount going to smaller groups is increasing.
